Objectives: To present an up-to-date review of studies investigating the efficacy, adverse events and vaccination regimens of the varicella vaccine and the new presentation combined with the vaccine for measles, mumps and rubella.
Introduction
Chickenpox is caused by the varicella-zoster virus (VZV), which only infects humans and some higher primates. Acquisition of the disease depends on age, immune status, vaccination status and exposure type.
Transmission is through intimate contact with sufferers during a period from 2 days before until 5 days after the appearance of vesicles. Clinical manifestations surface 10 to 21 days after contact and in more than 80% of cases include fever. Exanthema is absent in only 6% of affected individuals, the remainder exhibit cutaneous lesions that appear in clusters and progress rapidly from macules, through papules and vesicles to crusts. Normally, 5 to 6 days after the onset of exanthema, all lesions have reached the crusting phase. In the absence of secondary infection, varicella does not scar. In primary cases the number of cutaneous lesions is lower than in secondary cases (250 vs. 500, on average) and, generally, the disease is milder. Mortality is low (6.7/100,000), but lethality varies with age and immune status, being higher in groups at risk of complications (Table 1) . [1] [2] [3] [4] The most common complications are secondary bacterial infections of the mucosa, skin, soft tissues and upper and lower airways, which occur in more than 5% of children.
More severe complications, such as pneumonia and encephalitis, are rarer, although more severe; they occur in greater proportion among certain risk groups (Table 1) , but in absolute numbers they primarily affect previously healthy children. Reinfection by VZV appears to be rare in immunocompetent people. [1] [2] [3] [4] 
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Risk group Comments
People with congenital or acquired immunodeficiency, such as HIV carriers, those on high dose corticosteroids for long periods (≥ 2 mg/kg/day of prednisone or equivalent, for more than 14 days); patients with malignant neoplasms; undergoing bone marrow or solid organ transplantation or subjected to chemotherapy or radiotherapy
Pregnant women
Babies whose mothers presented varicella 5 days before or 2 days after giving birth
Premature infants with birth weight below 1,000 g or gestation < 28 weeks exposed to varicella during the neonatal period Varicella-zoster virus remains in the organism in a latent state after the primary infection, and its reactivation leads to the onset of zoster, manifested by lesions similar to those observed with varicella, but more localized, following the path of one or more nerves. The incidence of zoster in early childhood is low (20 to 60 cases/100,000 people/year), but increases with age and with conditions associated with immunodepression, such as leukemia, transplantation and HIV infection. [1] [2] [3] [4] The majority of varicella cases occur in children.
Seroepidemiological survey studies undertaken in Brazil revealed that almost half of the children tested had already been infected by 5 years of age. While there are major regional variations, children who live in crowded conditions or are looked after away from home contract the infection earlier and exhibit higher rates of complications. [4] [5] [6] [7] [8] Varicella cases occur all year round, but in temperate climates the majority of disease outbreaks are recorded during the end of winter and start of spring. [1] [2] [3] [4] Varicella vaccines 
Immunogenicity
Antibody production is related to the number of PFU in the vaccines, and also to age and immune status; however, even using the most potent vaccines, antibody production is many times weaker than after natural infections. [1] [2] [3] More than 95% of previously healthy children aged between 12 months and 12 years exhibit adequate seroconversion after a single dose of the vaccine. [1] [2] [3] In adolescents, adults and the immunodepressed, postvaccination seroconversion rates are lower and antibody titers decrease more quickly; therefore these individuals should be given two doses of the varicella vaccine, with a 4 to 8 week interval. [1] [2] [3] [4] [5] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] There is no interference in immunoresponse to the varicella vaccine when it is administered simultaneously with other vaccines recommended for children; however, when the varicella vaccine is administered less than 1 month after the measles, mumps and rubella vaccine (MMR), reduced seroconversion rates are observed in response to the varicella virus. [1] [2] [3] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Adverse events
The most common adverse events are: pain, erythema and edema at the site of vaccine administration (15 to 25%), generally mild; fever (14%) and mild exanthema (4%). Exanthema can appear 1 to 3 weeks after vaccination, and may be in the site of administration or in other sites.
The number of vesicles after vaccination is generally low, less than 10. [1] [2] [3] When the number of lesions after vaccination is greater than 30, a wild virus infection should be suspected, especially when these appear within the 2 first weeks of vaccination. 22 Other adverse events after vaccination are very rare.
A survey of adverse events associated with the vaccine after more than 16 million doses had been administered in the USA revealed that the vaccine is very safe. Although 19 cases of encephalitis and 24 of ataxia were recorded after vaccination, in none of these was infection by the Oka strain confirmed; in contrast, in two of these cases the wild virus was identified. None of the 14 deaths notified after vaccination was confirmed as being associated with the Oka strain and two were caused by wild viruses. 22 Anaphylactic reactions after vaccination are rare and are generally associated with the gelatin used as a stabilizer in the vaccine. [1] [2] [3] [4] 22 The vaccine virus is rarely isolated from healthy vaccinated people, since the majority do not exhibit cutaneous lesions and the risk of viral dissemination is directly associated with the presence of these lesions.
Children with leukemia exhibit an increased chance of developing cutaneous lesions after vaccination; but, even under these circumstances the risk of transmission to susceptible contacts is, at most, 17%, much lower than the risk associated with contact with people infected by the wild virus (> 80%). [1] [2] [3] [4] 18, 19 After the varicella vaccine was licensed in the USA, just three cases were confirmed of transmission of the vaccine virus from previously healthy people to domestic contacts, and, in all cases, the contacts developed mild disease, with low numbers of lesions. 22 The majority of reported cases of possible transmission of the vaccine virus were associated with infection by the wild virus. Comparing the low numbers of reports of vaccine virus transmission to non-immune contacts with the number of people vaccinated, this event appears to be extremely rare. [1] [2] [3] [4] 22 There is a direct relation between the number of cutaneous lesions and dissemination of the vaccine virus. In all cases of vaccine virus transmission, contacts had mild disease, without fever, and with a low number of cutaneous lesions. [1] [2] [3] [4] 19 Despite the low risk of In a controlled study in which 2,000 children aged 1 to 12 years were randomized to receive one or two doses of the vaccine (Oka/Merck ® ), protection observed 42 days after vaccination was 94.4% for a single dose and 98.3%
for two doses administered with a 3 month interval.
Some of the children who exhibited seroconversion presented mild cases of varicella during monitoring, known as modified varicella-like syndrome (MVLS).
While the risk of presenting MVLS was 3.3 times greater in the group given a single dose of the vaccine, the difference between the groups was small (7.7% for the single dose and 2.2% for the group given two doses). Number of deaths/million -USA population Source: Nguyen et al. 31 Studies undertaken with the Oka/GSK ® vaccine have also demonstrated excellent rates of post-vaccination seroconversion (> 98%); some of the children in this study were given the vaccine before reaching 1 year of age, without any increase in incidence or severity of postvaccination adverse events. [13] [14] [15] The principal factors associated with primary and secondary vaccination failure are listed in Table 3 . [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] The probability of a vaccinated individual suffering secondary vaccination failure is inversely proportional to the antibody titers 6 weeks after vaccination, [13] [14] [15] but almost all of those children who had secondary vaccination failure exhibited low severity varicella episodes, with few cutaneous lesions, the majority papules. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] It is rare for vaccinated children to present vesicles; since the number of vesicles is directly related to transmission of the disease, circulation of VZV is reduced in communities with high levels of vaccination coverage. [23] [24] [25] Varicella outbreaks recorded at day care centers have led to speculation that there may be a need for a second dose of the vaccine. 22, [26] [27] [28] Nevertheless, in many of these situations, cases occurred among children without Susceptible people older than 1 year and with negative history of varicellazoster, with no need for laboratory confirmation. Protection against herpes-zoster (HZ)
The incidence of zoster in healthy children is so low that, in order to discover the impact of routine vaccination on HZ incidence, it will be necessary to follow-up thousands of individuals for many years. [1] [2] [3] [4] Studies undertaken in the USA after the varicella vaccine had been introduced reported some cases of HZ, but it is very difficult to isolate the virus from lesions, and in some of the HZ that occurred after immunization, the virus isolated was a wild form. In the rare cases of zoster that occurred in vaccinated individuals, the disease was milder, with few lesions and resolution was faster than in those infected by the wild virus. There are reports that vaccination of schoolchildren reduces the incidence of zoster by three times, and everything indicates that vaccination should be capable of reducing the risk of zoster. [1] [2] [3] 33, 34 Two recently published studies that analyzed the impact of vaccination for varicella on the incidence of HZ in the USA reported different results. 33, 34 In both studies a significant reduction was observed in the number of cases of varicella in all study groups. However, in the first study 33 the rate of HZ was stable, whereas in the second there was a discrete increase in the number of reports of HZ. 34 Since zoster notification rates are variable, further studies are still needed to evaluate whether the reduction in varicella cases may lead to an increase in zoster.
A vaccine for HZ to be used with the elderly, produced by the Merck ® laboratory, was tested in a randomized, placebo-controlled manner with 38,546 people over 60 years. In the vaccinated group, the incidence of HZ was 51% below that for the placebo group. Furthermore, the incidence of postherpetic neuralgia in the vaccinated group was 61% lower than in the control group. Once licensed, this new vaccine should be recommended to reduce the incidence and morbidity associated with zoster in the elderly. 35 
Contraindications and precautions
The varicella vaccine contains live attenuated viruses and for that reason is contraindicated in the following situations.
General illness, with or without fever
Postpone vaccination so that possible adverse effects of vaccination will not be confused with symptoms from the underlying disease.
Congenital or acquired immunodeficiency
People with cell-based immunodeficiency should not be vaccinated, but some immunocompromised groups can be vaccinated on the public health system at the Special
Immunobiology Referral Centers (CRIE Centros de
Referência para Imunobiológicos Especiais). Table 4 simultaneously in different sites. 36, 37 A subset of the children was given a second dose of the MMRV vaccine around 3 months after the first dose.
Geometric mean titers (GMT) of antibodies for measles, mumps and rubella increased by around two times; for varicella, seroconversion reached 99.4%, and GMT increased more than 40 times (from 13.3 to 588.1 gpELISA units/mL). 36, 38 A second dose of the MMRV vaccine was administered at 4 and 6 years of age to children who had previously been given one dose of the MMR and V vaccines when already more than 12 months old. The seroconversion rate observed for varicella after the second dose was 98.9%, with antibody GMT increasing 12 times compared to results from before revaccination.
In the USA the vaccine was licensed to be administered in a single dose to children 12 months to 12 years old and can be given simultaneously with other vaccines recommended for the age group. 36 The MMRV/GSK ® vaccine was studied with children 12 to 18 months old, who were given two doses of the vaccine, with intervals of 6 and 8 weeks (group MMRV) or a dose of MMR simultaneously with a dose of V, followed by another dose of MMR (group MMR + V). After the second dose 100% of the children in both groups exhibited seroconversion for measles, rubella and varicella, while 98% had seroconverted for mumps in the MMRV group and 99% had done so in the MMR + V group. 39 Varicella and MMRV vaccines Bricks LF et al.
Another study compared two doses of the MMRV vaccine with two doses of the MMR + V vaccines, given at 9 and 12 months of age. Seroconversion rates were 100% in all children after the second dose (99.2% for mumps in the MMR + V group). Rubella antibody GMT was comparable for the two groups, with GMT for measles, mumps and varicella being higher in the MMRV group. 40 In Australia, the MMRV/GSK ® vaccine was licensed to be used in a two-dose regime, with an interval of 6 to 12 weeks, to be given before the end of the second year of life. The first dose can be given from 9 months of age onwards.
In all these studies, adverse events were similar among children in the MMRV and MMR + V groups. Only mild fever was more common among the children in the MMRV group. 36, 40 Final comments
In Brazil the varicella vaccine has not been added to the routine schedule and is only available free of charge at the CRIE for certain high-risk groups (Table 4) . Since the response to varicella vaccine is prejudiced in people with compromised immunoresponse, it is believed that mass vaccination is the best form of protecting at-risk groups since it confers collective immunity. has limited economic resources. 6 We hope that the measles, mumps, rubella, and varicella vaccine will soon be available in Brazil, since the use of combined vaccines facilitates compliance with recommendations for the use of new vaccines and makes wider vaccination coverage possible. 
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